BioCentury | Dec 24, 2019
Company News

Dec. 23 Company Quick Takes: Theravance partners with Pfizer; plus Fortress-AZ, Progenics, Tracon-Alphamab Oncology-3D Medicines

...data Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) plans to submit an NDA to FDA in 2H20 for PyL...
...prostate cancer. The company reported top-line data Monday from the Phase III CONDOR study showing PyL...
BioCentury | Oct 6, 2018
Finance

Seeking validation

...PXT3003 Charcot-Marie-Tooth Type 1A (CMT1A) disease Top-line Ph III data October Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) 18F-DCFPyL...
BioCentury | Dec 16, 2016
Clinical News

PyL: Ph II/III OSPREY started

...the open-label, North American Phase II/III OSPREY trial to evaluate a single dose of IV PyL...
...cancer with recurrence or metastatic disease. Progenics Pharmaceuticals Inc. (NASDAQ:PGNX), New York, N.Y. Product: 18F-DCFPyL, PyL...
...and pharmacokinetics Status: Phase II/III started Milestone: NA Julian Zhu (18F)DCFPyL PyL Progenics Pharmaceuticals Inc. Prostate-specific membrane antigen (PSMA) (FOLH1) (GCPII) 18F-DCFPyL...
Items per page:
1 - 3 of 3